|
Myeloid Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the EVI1 oncogene is associated typically with aggressive myeloid leukemia, but is also detectable in breast carcinoma where its contributions are unexplored.
|
28209621 |
2017 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
|
23770046 |
2013 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.
|
20084277 |
2010 |
|
Myeloid Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal translocations involving the EVI1 locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis.
|
18815193 |
2008 |
|
Myeloid Leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
|
14551738 |
2004 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
One of the genes associated with both murine and human myeloid leukemia is EVI1 (ecotropic viral integration 1 site).
|
12972028 |
2004 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, it is likely that overexpression of the zinc finger protein lacking the PR domain (EVI1 and MEL1S) in the leukemia cells is one of the causative factors in the pathogenesis of myeloid leukemia.
|
12816872 |
2003 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
|
12461752 |
2003 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that specific HDAc inhibitors may be useful in the treatment of Evi-1-induced neoplastic tumors, including myeloid leukemias.
|
11587364 |
2001 |
|
Myeloid Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast to MDS1/EVI1, EVI1 is often activated inappropriately by chromosomal rearrangements at 3q26 leading to inappropriate expression of the protein in hematopoietic cells and to myeloid leukemias, which are often characterized by abnormal megakaryopoiesis.
|
10557037 |
1999 |
|
Myeloid Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive expression of Evi-1 in hematopoietic cells, which is caused by retroviral insertions or chromosomal translocations and inversions, is closely associated with myelogenous leukemias and myelodysplastic syndromes in mice and humans.
|
10641791 |
1999 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
CBFA2 forms a fusion gene with ETO and MDS1/EVI1 in translocations in myeloid leukemia and with ETV6(TEL) in the t(12;21) common in childhood pre-B acute lymphoblastic leukemia.
|
9763573 |
1998 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
AML1, a gene on chromosome 21 encoding a transcription factor, is disrupted in the (8;21)(q22;q22) and (3;21)(q26;q22) chromosomal translocations associated with myelogenous leukemias; as a result, chimeric proteins AML1/ETO(MTG8) and AML1/Evi-1 are generated, respectively.
|
9473235 |
1998 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This translocation results in the fusion of TEL, a recently described ETS-like gene on 12p13, and AML1, which was shown to be involved in the formation of fusion genes with ETO and EVI1 in myeloid leukemias.
|
9498702 |
1997 |
|
Myeloid Leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two genes located at 3q26 have been implicated in development or progression of myeloid leukemia.They are MDS1 and EVI1.
|
9447815 |
1997 |
|
Myeloid Leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Retroviral activation of Evi-1 gene expression is one of the most common transforming events in murine myeloid leukemias.
|
1570317 |
1992 |